Glukoza 40 Braun

Glukoza 40 Braun is a 40 % w/v glucose monohydrate solution for injection, supplied as an intravenous preparation. It is classified as a carbohydrate solution used in parenteral nutrition and for the treatment of hypoglycemia. The product is manufactured for the European market and is available by prescription only, providing a rapid source of glucose to support cellular metabolism when blood sugar is low in patients.

Glukoza 40 Braun is indicated for clinical situations where rapid elevation of blood glucose is required or when intravenous carbohydrate provision is needed as part of nutritional support.

- Treatment of acute hypoglycemia in adults and children when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in conjunction with other intravenous solutions. - Support during surgical procedures or critical care when metabolic demand for glucose is increased. - Adjunct therapy in certain metabolic disorders requiring controlled glucose infusion.

The safety profile of Glukoza 40 Braun reflects the pharmacologic effects of intravenous glucose; most reactions are related to the solution itself or to rapid changes in plasma glucose. These events are generally dose‑related and resolve with appropriate clinical management.

Common: - Mild hyperglycemia or transient rise in blood glucose levels. - Local irritation or pain at the injection site. - Electrolyte imbalance, most often a temporary shift in potassium or sodium levels. - Nausea or vomiting, especially with rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis or dehydration. - Hypersensitivity reactions such as rash, urticaria, or anaphylaxis. - Volume overload in patients with compromised cardiac or renal function.

When administering Glukoza 40 Braun, clinicians should observe specific precautions to minimize risks associated with rapid glucose delivery and fluid volume.

- Verify blood glucose level before infusion and monitor frequently during therapy. - Adjust infusion rate in patients with impaired renal or cardiac function to avoid fluid overload. - Use aseptic technique; discard any solution that appears discolored or contains particles. - Consider electrolyte status, especially potassium and sodium, and correct abnormalities before administration. - Avoid use in patients with known hypersensitivity to glucose preparations. - Do not exceed recommended concentration; dilution may be required for pediatric patients.

Glukoza 40 Braun may interact with other agents that influence blood glucose, electrolyte balance, or intravascular volume; awareness of these interactions helps ensure safe co‑administration.

Avoid: - Concurrent use with high‑dose insulin infusions without appropriate glucose monitoring. - Administration together with other hypertonic carbohydrate solutions, which can cause excessive plasma osmolality.

Use with caution: - Co‑administration with diuretics; monitor electrolytes closely. - Use alongside vasopressors; assess fluid status to prevent overload. - Combination with other parenteral nutrition components; adjust total carbohydrate load. - When given with beta‑blockers, glucose metabolism may be altered; monitor glycemic response. - In patients receiving corticosteroids, hyperglycemia risk is increased; adjust glucose infusion accordingly.